Detalles de la búsqueda
1.
Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12.
Cancer Immunol Immunother
; 72(8): 2783-2797, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37166485
2.
Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9.
PLoS One
; 19(3): e0287733, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38427670
3.
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.
Int J Cancer
; 133(3): 624-36, 2013 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23364915
4.
Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies.
Cells
; 12(12)2023 06 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37371081
5.
Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine.
Front Oncol
; 13: 1321318, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38260854
6.
Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFßRII agent: Current status.
Exp Biol Med (Maywood)
; 247(13): 1124-1134, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35473390
7.
Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
J Immunother Cancer
; 10(6)2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35764364
8.
Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity.
JCI Insight
; 7(5)2022 03 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35260537
9.
Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-ß signaling enables PD-L1-mediated tumor eradication.
J Clin Invest
; 132(8)2022 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35230974
10.
Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses.
Cancer Immunol Immunother
; 60(9): 1227-42, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21544650
11.
Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa.
Oncoimmunology
; 10(1): 1915561, 2021 05 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33996267
12.
Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape.
Nat Commun
; 12(1): 5151, 2021 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34446712
13.
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
J Immunother Cancer
; 8(1)2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32303618
14.
Dual targeting of TGF-ß and PD-L1 via a bifunctional anti-PD-L1/TGF-ßRII agent: status of preclinical and clinical advances.
J Immunother Cancer
; 8(1)2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32079617
15.
Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
Clin Cancer Res
; 26(3): 704-716, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31645354
16.
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.
Front Oncol
; 10: 581801, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33747894
17.
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
J Immunother Cancer
; 8(1)2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32209603
18.
Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
J Immunother Cancer
; 7(1): 82, 2019 03 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30898149
19.
Correction to: Immunotherapy Utilizing the Combination of Natural Killer- and Antibody Dependent Cellular Cytotoxicity (ADCC)-Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition.
J Immunother Cancer
; 7(1): 234, 2019 Sep 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31477176
20.
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex.
Oncoimmunology
; 8(2): e1532764, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30713787